Zacks Investment Research·Sep 11, 2026
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?Techne (TECH) reported earnings 30 days ago. What's next for the stock?
Bio-Techne's investment case is anchored by a fortress balance sheet with a 0.14 debt-to-equity ratio and $264.7M in cash, providing significant strategic flexibility. However, the core business faces headwinds, with revenue growth decelerating to just 1.3% in...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has stalled at 1.3% in 2026Q4, while operating margins of 23.1% remain well below historical averages, indicating that SG&A expenses consuming ~35% of revenue are eroding profitability despite gross margin resilience.
Hedge fund ownership of TECH increased from 34 to 37 portfolios in Q2, indicating growing institutional confidence.
The company's core business segments remain robust, supporting the bullish investment thesis.
Bio-Techne is positioned for long-term total addressable market growth across its biotech solutions.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | $0.52+0.2% vs $0.52 | $321M+2.1% vs $315M |
Q2 2026 May 6, 2026 | $0.53-3.6% vs $0.55 | $311M-1.5% vs $316M |
Q1 2026 Feb 4, 2026 | $0.46+7.0% vs $0.43 | $296M+1.9% vs $290M |
Q4 2025 Nov 5, 2025 | $0.42-0.3% vs $0.42 | $287M-1.6% vs $291M |
Techne (TECH) reported earnings 30 days ago. What's next for the stock?
CMB.TECH delivered a 134% return in under a year, driven by a strategic dry bulk focus and strong tanker markets. I recently interviewed the CEO and CFO to get updates on the dry bulk industry and company-specific strategy. CMBT maintains a flexible, discretionary dividend policy, targeting 50–60% of net income over time while preserving capital for counter-cyclical opportunities.
ANTWERP, Belgium, 8 September 2026, 08:00 a.m. CET – CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) (NYSE: CMBT, Euronext Brussels: CMBT en Euronext Oslo Børs: CMBTO) invites its shareholders to participate in the Special General Meeting that will be held on Thursday 8 October 2026.
Fiscal 2026 highlights: Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More than half of the company's electricity consumption now comes from renewable sources First comprehensive Scope 3 emissions inventory completed MINNEAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.
Benchmark TECH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Bio-Techne Corporation (TECH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $72.55 | $11.36B | 62.54 | -0.38% | 14.97% | 8.98% | 0.44% | |
| $186.70 | $10.54B | 217.09 | 16.36% | 5.29% | 1.98% | — | |
| $13.98 | $3.04B | -349.50 | -2.71% | -0.91% | -0.37% | — | |
| $34.28 | $1.58B | -28.10 | 3.55% | -20.02% | -7.56% | — | |
| $143.31 | $15.99B | 68.90 | 3.67% | 8.16% | 3.27% | — | |
| $15.92 | $2.07B | -18.95 | 191.39% | -171.59% | -15.62% | — |
Bio-Techne Corporation (TECH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Bio-Techne Corporation (TECH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
Jun 26, 2026·SEC
Jun 25, 2026·SEC
Get notified when TECH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bio-Techne Corporation (TECH) stock FAQ — growth, dividends, profitability & financials explained
Bio-Techne Corporation (TECH) reported $1.22B in revenue for fiscal year 2026. This represents a 1895% increase from $60.9M in 1997.
Bio-Techne Corporation (TECH) saw revenue decline by 0.4% over the past year.
Yes, Bio-Techne Corporation (TECH) is profitable, generating $181.9M in net income for fiscal year 2026 (15.0% net margin).
Yes, Bio-Techne Corporation (TECH) pays a dividend with a yield of 0.44%. This makes it attractive for income-focused investors.
Bio-Techne Corporation (TECH) has a return on equity (ROE) of 9.0%. This is below average, suggesting room for improvement.
Bio-Techne Corporation (TECH) generated $263.2M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
